4- (2- (2- ((2r)- 2- methyl- 1- pyrrolidinyl)ethyl)- 5- benzofuranyl)- benzonitrile (ABT 239)

Also Known As:

ABT 239; benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-; (R)-4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile; 4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile; ABT-239; ABT239

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)- benzonitrile: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)- benzonitrile: 3

Experts

1.	Rueter, Lynne E: 3 articles (05/2013 - 04/2005)
2.	Zhang, Min: 3 articles (05/2013 - 04/2005)
3.	Ballard, Michael E: 2 articles (05/2005 - 04/2005)
4.	Decker, Michael W: 2 articles (05/2005 - 04/2005)
5.	Faghih, Ramin: 2 articles (05/2005 - 04/2005)
6.	Fox, Gerard B: 2 articles (05/2005 - 04/2005)
7.	Basso, Ana M: 1 article (05/2013)
8.	Brown, Jordan W: 1 article (05/2013)
9.	Whitehead, Caroline A: 1 article (05/2013)
10.	Cowart, Marlon: 1 article (05/2005)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 04/01/2005 - "In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0-3.0 mg/kg) and N40 (1.0-10.0 mg/kg). " 05/01/2013 - "ABT-239 was also investigated in methylazoxymethanol acetate (MAM) treated rats, a neurodevelopmental model for schizophrenia. " 04/01/2005 - "In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia." 04/01/2005 - "Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist."
2.	Catalepsy 05/31/2005 - "In contrast, no catalepsy-enhancing effects were observed when selective non-imidazole H3R antagonists, ABT-239 and A-431404, were coadministered with haloperidol and/or risperidone. "
3.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 04/01/2005 - "In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia."
4.	Alzheimer Disease (Alzheimer's Disease) 04/01/2005 - "In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia."

Related Drugs and Biologics

1.	Risperidone (Risperdal Consta)
2.	Histamine H3 Receptors (Histamine H3 Receptor)
3.	Methylazoxymethanol Acetate
4.	Haloperidol (Haldol)
5.	benzofuran
6.	imidazole
7.	benzonitrile